Eden Research sowing seeds of success

A huge congratulations to Milton Park-based Eden Research, a sustainable biopesticide company specialising in crop protection, health and consumer products, after it announced its US authorisation and expectations of a 33% rise in half year revenues for 2022, putting itself on track to reach the full year’s target of £1.4 million.

Eden’s products, largely used to protect crops and increase yields in the global agriculture industry, are formed using natural plant chemistry meaning that they are plastic-free and provide ease of use. Two of Eden’s projects are currently commercially available, the first of them being Mevalone, a bio-fungicide available in 14 countries, and the second, Cedroz^TM, a nematicide made in partnership with Eastman Chemical available in 29 countries.

As an established Plc and the UK’s only Alternative Investment Market (AIM) company in the field of developing innovative biopesticide products and technologies, this revenue projection is yet another achievement contributing to Eden Research’s exciting journey at Milton Park.

Landmark US authorisation

After a four-year review period, Eden Research has now gained federal US authorisation for both its formulated products and portfolio of active ingredients, making the US the nineteenth country to grant Eden this specific authorisation. This marks a key milestone in achieving their aim of US commercialisation, sparking great potential to significantly increase its revenues yet again.

Excitingly, the State of California, which represents the most significant market for Eden’s products, has already granted its authorisation subject to US Environmental Protection Agency (EPA) approval, taking the company even closer to its commercialisation goals.

Exciting times ahead

Looking ahead, regulatory authorisation for Eden’s first seed treatment is also on the horizon where, if gained, will amount to significant sales to Corteva Agriscience, a leading agriculture input company also based at Milton Park, following their official Commercialisation, Supply and Distribution Agreement.

With these promising projects in progress on top of what has already been achieved, we expect that Eden Research may see many more successes in the future at Milton Park.

Sean Smith, CEO at Eden Research, said: “2022 is proving to be a good year of progress for Eden Research with regards to revenue and the growth of our product offering. Milton Park has provided us with a great base to carry out the innovative work underpinning these achievements.

“We look forward to what’s in store for us for the rest of this year as we seek to progress more key milestones and collaborative company partnerships.”